Navidea Biopharmaceuticals Announced The Sale Of Preferred Shares Totaling $1.1M To New Existing Investors; It Provides Additional Capital To Fuel Navidea's NAV3-32 And NAV3-33 Trials Toward Completion
Navidea Biopharmaceuticals Announced The Sale Of Preferred Shares Totaling $1.1M To New Existing Investors; It Provides Additional Capital To Fuel Navidea's NAV3-32 And NAV3-33 Trials Toward Completion
Navidea Biopharmaceuticals宣布向新的现有投资者出售总额为110万美元的优先股；它为推动Navidea的 NAV3-32 和 NAV3-33 试验接近完成提供额外资金
Navidea Biopharmaceuticals Announced The Sale Of Preferred Shares Totaling $1.1M To New Existing Investors; It Provides Additional Capital To Fuel Navidea's NAV3-32 And NAV3-33 Trials Toward Completion
Navidea Biopharmaceuticals宣布向新的现有投资者出售总额为110万美元的优先股；它为推动Navidea的 NAV3-32 和 NAV3-33 试验接近完成提供额外资金